in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Peregrine Pharmaceuticals, Seaside Therapeutics and Eucodis.
Peregrine Pharmaceuticals has appointed Robert Garnick as head of regulatory affairs. Garnick previously worked at Genentech for 24 years and since leaving the biotech in 2008 has founded Lone Mountain Biotechnology and Medical Devices.
He has also been “extensively involved” with the International Conference on Harmonisation (ICH) and has experience in analytical methodology, process validation and regulatory review in the US and Europe.
Seaside Therapeutics has made three executive appointments, including recruiting John Amedio as vice president (VP), manufacturing and process development.
Amedio previously held a similar role at Ziopharm Oncology and has also worked in executive positions at Epic Pharmaceuticals and Sandoz Research Institute. Seaside has also appointed Daniel Geffken as chief operating officer and Roger Rush as VP, preclinical development.
Bhupinder Hundle has been appointed as senior VP marketing & sales at Eucodis Bioscience, a manufacturer of enzymes for the chemical and pharma industry. Before joining Eucodis Hundle worked at Lonza and has also worked at Amaxa.
Xoma has appointed Susan Kramer as VP, project and alliance management. Kramer has 25 years experience at companies including Genentech, Anesiva and Corthera.
Catalyst Pharmaceutical Partners has appointed Steven Miller as chief scientific officer and Jack Weinstein will take formal responsibility for the company’s business development activities.
Both already hold positions at Catalysts and have now taken on additional responsibilities.
Joachim Schupp has been appointed as chief medical officer at Transdel Pharmaceuticals. Schupp has 25 years experience in the industry at companies including Novartis, where he spent 19 years, Adventrx Pharmaceuticals and ProSanos.